Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Doctor talking to patient while taking notes.

ESMO 2021, News

Adjuvant Pembrolizumab Prolongs Relapse-Free Survival in Stage II Melanoma

Andrea S. Blevins Primeau, PhD, MBA

September 21, 2021

Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.

ESMO 2021, News

Long-Term Follow-up Confirms Efficacy, Safety of Nivolumab Plus Chemotherapy in Gastrointestinal Cancers

Andrea S. Blevins Primeau, PhD, MBA

September 21, 2021

The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.

ESMO 2021, News

TARE Prolongs PFS, Not OS, in Colorectal Cancer With Liver Metastases

Andrea S. Blevins Primeau, PhD, MBA

September 22, 2021

The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.

ESMO 2021, News

Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2021

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

Multiple patients having chemotherapy in a room

ESMO 2021, News

dd-MVAC Regimen ‘Should Be Gold Standard’ for Muscle-Invasive Bladder Cancer

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2021

Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.

ESMO 2021, News

Trastuzumab Deruxtecan: A New Standard for Second-Line Therapy in HER2+ Metastatic Breast Cancer?

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2021

Trastuzumab deruxtecan significantly improved progression-free survival.

ESMO 2021, News

Long-Term COVID-19 Symptoms Linked to Treatment, Survival of Cancer Patients

Andrea S. Blevins Primeau, PhD, MBA

September 17, 2021

Long-term symptoms included shortness of breath, chronic fatigue, and neurocognitive dysfunction.

ESMO 2021, News

Cancer Cases in Europe Projected to Increase About 20% by 2040

Andrea S. Blevins Primeau, PhD, MBA

September 17, 2021

The researchers also projected an increase in cancer deaths.

A blood smear of chronic myeloid leukemia cells.

ASCO 2021, News

Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia

Andrea S. Blevins Primeau, PhD, MBA

June 7, 2021

A 45-mg starting dose, reduced to 15 mg, produced the best outcome.

ASCO 2021

High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL

Andrea S. Blevins Primeau, PhD, MBA

June 5, 2021

Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.